Scarica l'app Stockscreener
2.92
2.67%
-0.08
Dopo l'orario di chiusura:
2.92
Precedente Chiudi:
$3.00
Aprire:
$2.81
Volume 24 ore:
30,594
Relative Volume:
0.65
Capitalizzazione di mercato:
$75.93M
Reddito:
$1.79M
Utile/perdita netta:
$-70.90M
Rapporto P/E:
-0.1879
EPS:
-15.54
Flusso di cassa netto:
$-34.95M
1 W Prestazione:
-14.87%
1M Prestazione:
+1.39%
6M Prestazione:
+30.36%
1 anno Prestazione:
-24.74%
Intervallo 1D:
$2.81
$3.2799
Intervallo di 1 settimana:
$2.81
$3.56
Portata 52W:
$1.5201
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Nome
Senti Biosciences Inc
Settore
Industria
Telefono
(650) 382-3281
Indirizzo
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Confronta SNTI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
2.92 | 75.93M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-07 | Iniziato | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Borsa (SNTI) Ultime notizie
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Manila Times
Groundbreaking Clinical Trial Data: SENTI-202 Shows Promise for Hard-to-Treat Blood Cancer - Stock Titan
Virtu Financial LLC Acquires Shares of 13,356 Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World
Senti Biosciences Files Shelf for 52.9 Million Shares - MarketScreener
Senti Biosciences Files For Shelf Of Up To 52.9 Mln Shares Of Common Stock By Selling StockholdersSEC Filing - Marketscreener.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire
Senti Bio Reports Promising Trial Results and Financial Growth - TipRanks
Senti Biosciences Inc. (SNTI) reports earnings - Quartz
Senti Biosciences, Inc. SEC 10-K Report - TradingView
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights - The Manila Times
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and ... - The Bakersfield Californian
Hogs Trading Mixed on Thursday - The Globe and Mail
Breakthrough: Senti Bio's AML Therapy Shows 67% Complete Remission Rate, Raises $47.6M - Stock Titan
Will Senti Biosciences Turn Heads In 2025? - RTTNews
Senti Bio appoints new board member, grants stock options - Investing.com
Senti Bio Appoints Feng Hsiung To Board Of Directors -March 13, 2025 at 05:31 pm EDT - Marketscreener.com
Senti Bio Appoints Feng Hsiung to Board of Directors - The Manila Times
Senti Biosciences Expands Board with New Appointment - TipRanks
Senti Biosciences Announces Board Changes and Equity Plan Update - Investing.com
Senti Biosciences secures stockholder nods for equity plans By Investing.com - Investing.com Australia
Senti Biosciences secures stockholder nods for equity plans - Investing.com
Comparing Senti Biosciences (NASDAQ:SNTI) and Windtree Therapeutics (NASDAQ:WINT) - Defense World
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.
4 Reasons Tesla Stock Is Crashing in 2025: Should You Buy the Dip? - The Globe and Mail
Lindsay Androski named CEO of Arbutus - BioCentury
Senti Biosciences Appoints New CFO Jay Cross - TipRanks
Senti Bio appoints Jay Cross as CFO - TipRanks
Senti Biosciences expands leadership with new CFO and SVP By Investing.com - Investing.com Canada
Senti Biosciences expands leadership with new CFO and SVP - Investing.com India
Senti Bio Strengthens Leadership Team with Strategic Hires - The Manila Times
Senti Biosciences (NASDAQ:SNTI) versus IN8bio (NASDAQ:INAB) Critical Contrast - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc - ACCESS Newswire
Senti Biosciences CEO Timothy Lu sells shares worth $18,338 - MSN
Senti Biosciences executive sells $6,074 in stock - MSN
Senti Biosciences Renews Consulting Agreement with Yvonne Li - TipRanks
Senti Biosciences CFO transitions to consultant role - Investing.com
Senti Biosciences CFO transitions to consultant role By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire
US Penny Stocks To Watch In January 2025 - Yahoo Finance
Critical Comparison: Senti Biosciences (NASDAQ:SNTI) and Ginkgo Bioworks (NYSE:DNA) - Defense World
Senti Bio Announces Additional $11.5 Million of Financing - The Manila Times
Senti Biosciences secures additional $10 million investment By Investing.com - Investing.com
Senti Bio announces additional $11.5M in financing - TipRanks
Senti Biosciences Inc Azioni (SNTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):